Argent Biopharma Limited Appointment of UK Corporate Broker
21 Junio 2024 - 1:00AM
RNS Regulatory News
RNS Number : 2919T
Argent Biopharma Limited
21 June 2024
21
June 2024
Argent BioPharma
Ltd.
(Argent BioPharma or the Company)
Appointment of UK Corporate
Broker
Argent BioPharma, an innovative
multidisciplinary drug discovery company within the
biopharmaceutical sector, is pleased to announce the appointment of
Shore Capital Stockbrokers Limited as the Company's UK Corporate
Broker with immediate effect.
Roby Zomer, CEO & Managing Director of Argent BioPharma,
commented:
"We are delighted to announce the
appointment of Shore Capital as our new UK Corporate Broker. This
is a further step in our comprehensive restructuring process to
position Argent BioPharma in pioneering drug discovery within the
biopharmaceutical sector, supported by the strengthening of our
management team and advisory board. We look forward to working with
the team at Shore Capital as we seek to enhance our visibility and
engagement with investors."
-Ends-
Authorised for release by the board of directors, for further
information please contact:
About Argent
BioPharma
Argent BioPharma Limited (the
"Company") (ASX: RGT; LSE: RGT; ORCQB: RGTLF) is a Clinical-Stage,
Revenue Generating Biopharmaceutical Company committed to providing
accessible medical treatments for unmet medical needs, to bridge
the gap where medical solutions currently fall short. The
Group focuses on the Multidisciplinary method with Nanotechnology,
developing multi-target therapies for comprehensive disease
management, especially relating to the
Central nervous system ("CNS") and Immunology treatments.
About Shore Capital
Shore Capital is an independent
securities business offering investment banking, research, sales
and trading services to companies on both the Main Market and
AIM.
Follow us through our social media channels:
LinkedIn: Argent
BioPharma
Twitter: @ArgentBioPharma
Facebook: Argent BioPharma
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our
Privacy
Policy.
END
APPFLFVRRTIIFIS
Argent Biopharma (LSE:RGT)
Gráfica de Acción Histórica
De Jun 2024 a Jul 2024
Argent Biopharma (LSE:RGT)
Gráfica de Acción Histórica
De Jul 2023 a Jul 2024